Dick Simon

Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world. Visit sensorium.bio to learn more.

Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, is a funding collaborative created to support the exceptional scientists and organizations working on psychedelic clinical trials and to ensure psychedelic treatments reach all who can benefit. Emerging research indicates that psychedelics have the potential to be a breakthrough in treating PTSD, depression, addiction, and other conditions. PSFC was born in 2017 out of a realization that psychedelic medicine has the potential to make an enormous impact and has an achievable path to regulatory approval, but has been systemically underfunded. Since PSFC’s founding, we have grown into a community of many of the leading funders of psychedelic medicine supporting organizations at the cutting edge of psychedelic research with funding and expert support. PSFC has funded several organizations at the forefront of the psychedelic field, and in 2020, we completed a $30 million fundraising campaign in partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support the completion of phase 3 clinical trials of MDMA-assisted psychotherapy. PSFC’s current areas of focus include supporting broad and equitable access to high-quality MDMA-assisted psychotherapy post-FDA approval, and supporting the implementation of Oregon’s Measure 109, which authorizes psilocybin therapy in the state, to ensure the program also provides broad and equitable access to high-quality care.